Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

Table 1

Randomized trials with neoadjuvant trastuzumab.

Study (ref.)	No. of patients	Clinical stage	Neoadjuvant chemotherapy	pCR rate (%)	cCR (%)	Breast-conserving surgery rate (%)
Buzdar et al. [4, 5],; phase III	42	II–IIIA	P (4 c) → FEC (4 c)	*Trastuzumab: 65%; *No trastuzumab: 26%	Trastuzumab: 87%; No trastuzumab: 47%	Trastuzumab: 53%; No trastuzumab: 56.5%
H2269s [6],; phase II	30	II-III	Doc + carboplatin; (4 c)	^†Trastuzumab: 40%; ^†No trastuzumab: 7.1%	NR	NR
ABCSG-24; [7], phase III	90	T1–4 (except T4d), any N	ED ± Cap (6 c)	^#Trastuzumab: 40%; ^#No trastuzumab: 26.7%	NR	Trastuzumab: 69%; No trastuzumab: 79%
NOAH [8],; phase III	235	T3N1, T4, or any T N2-3	Doxo + P (3 c) → P (4c) → CMF (3 c)	*Trastuzumab: 38%; *No trastuzumab: 19%	Trastuzumab: 87%; No trastuzumab: 74%	^‡Trastuzumab: 23%; ^‡No trastuzumab: 13%
REMAGUS 2 [9], phase II	120	II-III	EC (4 c) → Doc (4 c)	*Trastuzumab: 26%; *No trastuzumab: 19%	Trastuzumab: 34%; No trastuzumab: 22%	Trastuzumab: 47%; No trastuzumab: 47%

pCR: pathologic complete response; cCR: clinical complete response; NR: not reported; P: paclitaxel; FEC: 5-fluorouracil + epirubicin + cyclophosphamide; Doc: docetaxel; ED: epirubicin + docetaxel; Cap: capecitabine; Doxo: doxorubicine; CMF: cyclophosphamide + methotrexate + 5-fluoro-uracile; EC: epirubicin + cyclophosphamide.
pCR: *no invasive residual tumor in breast and axilla; ^†no invasive residual tumor in breast only; ^#definition not reported.
^‡[11].